Publication: Efectos secundarios de tipo metabólico asociados al tratamiento con antipsicóticos de segunda generación en niños, adolescentes y adultos
Loading...
Files
Official URL
Full text at PDC
Publication Date
2019-05-28
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
Algunos estudios sugieren que el riesgo de experimentar efectos secundarios de tipo metabólico en pacientes tratados con antipsicóticos de segunda generación (ASG) puede estar incrementado en niños y adolescentes respecto a adultos. Hasta el momento, ningún estudio prospectivo ha explorado de forma específica el efecto de la edad sobre este tipo de efectos secundarios en pacientes pediátricos y adultos con mínima exposición previa a antipsicóticos, teniendo en cuenta los cambios antropométricos esperables por la edad en el grupo de pacientes pediátricos. Hipótesis: 1) El tratamiento con ASG durante 24 semanas estará asociado con aumento de peso y alteraciones metabólicas en pacientes pediátricos y adultos. 2) Existirá un perfil diferencial de efectos secundarios según el antipsicótico, con mayor aumento de peso en los pacientes tratados con olanzapina en ambos grupos de edad. 3) El tratamiento con ASG durante 24 semanas se asociará con mayores alteraciones en la composición corporal en los pacientes pediátricos que en adultos. 4) El efecto de los cambios en la composición corporal sobre el desarrollo de algunas alteraciones metabólicas será mayor en el grupo de pacientes pediátricos que en adultos. 5) Algunas variables demográficas y clínicas modularán las trayectorias individuales de cambio en las variables de riesgo metabólico durante el seguimiento en ambos grupos de edad...
Preliminary evidence suggests that children and adolescents treated with second-generation antipsychotics (SGA) may be at higher risk for experiencing metabolic adverse effects than adults. To our knowledge, no previous prospective study has specifically explored the effect of age on the risk of metabolic side effects in pediatric and adult patients with minimal prior exposure to antipsychotics, while accounting for the age-expected body composition changes in the group of pediatric patients. Hypotheses: 1) Treatment with SGA for 24 weeks will be associated with weight gain and significant changes in other metabolic measures in pediatric and adult patients. 2) There will be a differential profile of adverse effects depending on the antipsychotic, with greater weight gain in patients treated with olanzapine in both age groups. 3) Treatment with SGAs for 24 weeks will be associated with greater changes in body composition in the group of pediatric patients relative to the group of adult patients. 4) The effect of changes in body composition on the development of some metabolic disturbances will be greater in the group of pediatric patients than in adult patients. 5) Some demographic and clinical variables will modulate the individual trajectories of changes in body composition and metabolic measures and the risk of developing metabolic complications during follow-up in both age groups...
Preliminary evidence suggests that children and adolescents treated with second-generation antipsychotics (SGA) may be at higher risk for experiencing metabolic adverse effects than adults. To our knowledge, no previous prospective study has specifically explored the effect of age on the risk of metabolic side effects in pediatric and adult patients with minimal prior exposure to antipsychotics, while accounting for the age-expected body composition changes in the group of pediatric patients. Hypotheses: 1) Treatment with SGA for 24 weeks will be associated with weight gain and significant changes in other metabolic measures in pediatric and adult patients. 2) There will be a differential profile of adverse effects depending on the antipsychotic, with greater weight gain in patients treated with olanzapine in both age groups. 3) Treatment with SGAs for 24 weeks will be associated with greater changes in body composition in the group of pediatric patients relative to the group of adult patients. 4) The effect of changes in body composition on the development of some metabolic disturbances will be greater in the group of pediatric patients than in adult patients. 5) Some demographic and clinical variables will modulate the individual trajectories of changes in body composition and metabolic measures and the risk of developing metabolic complications during follow-up in both age groups...
Description
Tesis de la Universidad Complutense de Madrid, Facultad de Medicina, Departamento de Medicina Legal, Psiquiátrica y Patología, leída el 08/02/2019